Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Collection Kit used for collection, transport, and storage of fecal specimens for nucleic acid analyses; and GA-map Covid-19 Fecal Test, a non-invasive test with an easy-to-use home sampling procedure. Further, it offers laboratory services; and bioinformatic analysis services. The company develops rapid microbiome-based PCR test. Genetic Analysis AS was founded in 2008 and is headquartered in Oslo, Norway.
Metrics to compare | GEAN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGEANPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −4.4x | −0.5x | |
PEG Ratio | −0.08 | −0.08 | 0.00 | |
Price/Book | 1.6x | 0.9x | 2.6x | |
Price / LTM Sales | 2.1x | 2.4x | 3.1x | |
Upside (Analyst Target) | - | 67.1% | 58.4% | |
Fair Value Upside | Unlock | 11.3% | 9.3% | Unlock |